Int. Journal of Clinical Pharmacology and Therapeutics, Volume 64 (2026) - November (620 - 622)

Tranilast/roxithromycin with topical tacrolimus in refractory atopic facial eczema: Case report

Yasuhiro Horiuchi
Division of Dermatology, Tsuruse Orthopedic Clinic, Saitama, Japan

Add to Cart  

 

DOI 10.5414/CP204924

Abstract

One challenge in atopic dermatitis is facial eczema, which requires delicate management because of the sensitive nature of facial skin. This report presents a 30-year-old male patient with facial eczema associated with atopic dermatitis, which could not be cured by conventional treatment, even with the continuation of oral betamethasone. The facial lesions were treated with pediatric 0.03% tacrolimus ointment. The patient was administered 200 mg/day tranilast and 300 mg/day roxithromycin. Within 3 weeks, his eczematous lesions on the face, as well as the severe itching, were completely cured. Addition of this combination therapy may be a promising therapeutic strategy for treating uncontrollable atopic dermatitis, particularly for facial eczema and itching.

Author Details

Authors

Departments

  • Division of Dermatology, Tsuruse Orthopedic Clinic, Saitama, Japan

Address

Yasuhiro Horiuchi, MD
Division of Dermatology
Tsuruse Orthopedic Clinic
201-11 Fujikubo, Miyoshi
354-0041 Saitama, Japan
Email: [email protected]

Log in for Subscribers

Citation

Yasuhiro Horiuchi. Tranilast/roxithromycin with topical tacrolimus in refractory atopic facial eczema: Case report
. Int J Clin Pharmacol Ther. 2026; 64: 620-622. doi: 10.5414/CP204924. Pubmed: https://pubmed.ncbi.nlm.nih.gov/42638546/; PMID: 42638546.

###article_not_exists_msg###

Warenkorb Übersicht

Warenkorb Übersicht
Typ Anz Rabatt MwSt Preis
Der Warenkorb ist leer
Ihr Warenkorb